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Abstract
Purpose: To report the therapeutic outcome of ultrasound-guided intralesional injection of 
bleomycin in the treatment of cutaneous hemangiomas and vascular malformations.
Material & Methods: The medical records of patients with cutaneous hemangiomas and 
vascular malformations treated with the intralesional injection of bleomycin under ultrasound 
guidance between August 2009 and June 2013 at the Indus Hospital, Karachi were reviewed 
retrospectively using a computerized medical record information management system. Data 
were extracted using a pre-coded performa that included patient demographics, type and 
location of lesion, number of treatments, presenting/pre- and post-treatment clinical symptoms 
(pain, swelling, heaviness, size, discoloration), ultrasound appearance and vascularity, and 
post-treatment side effects. The dose range of bleomycin was 0.5-1.0 mg/kg, but not exceeding 
15 mg in a single session. A maximum of four treatments were given in any given patient 
except for one, who presented with recurrence after a year of complete resolution. Therapeutic 
outcome was determined using review of ultrasound images and recorded clinical assessment. 
Treatment response was categorized as: (i) complete resolution [more than 90% reduction]; (ii) 
substantial reduction [more than 50% reduction]; (iii) mild reduction [25% reduction]; or, (iv) no 
improvement [<10% reduction].  
Results: A total of 30 patients (16 female, 14 male), ranging in age from 8 months to 48 years 
(mean age 10.2 years), were treated from 2009 to 2013. There were 23 hemangiomas. Seven 
were vascular malformations, of which five were lymphatic malformations and two were venous 
malformations. Twenty-eight lesions were located in the head and neck region, and two were 
peripheral. In 24 of the 30 patients (76%), treatment had been completed. In six patients (21%) 
treatment was ongoing at the time of this report. Seventeen of the 23 hemangiomas (74%) were 
completely resolved clinically and on ultrasound, five (22%) showed substantial improvement 
and one (4%) showed mild improvement. In five of the seven vascular malformations (71%) 
lymphatic malformations resolved completely, and two (29%) venous malformations showed 
substantial improvement. Of the 13 patients presenting with discoloration, there was complete 
resolution in one (7.7%), marked reduction in 11 (84.6%) and mild reduction in one (7.7%).  Of 
seven patients presenting with pain, there was complete resolution in two (28.6%), marked 
reduction in two (28.6%), mild reduction in two (28.6%), and no improvement in one (14.3%). 
There were no pulmonary complications. 
Conclusion: Ultrasound-guided intralesional injection of bleomycin is an option to consider 
for the treatment of certain types of cutaneous hemangiomas and vascular malformations. 
Prospective studies should be undertaken to understand the various factors contributing to 
therapeutic success.
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Introduction
HEMANGIOMAS and vascular malformations are developmental 
benign lesions that can occur in any organ. Frequently they 
are incidentally discovered. Internal hemorrhage may result in 
serious complications. Cutaneous hemangiomas and vascular 
malformations, on the other hand, are readily detectable and may 
result in functional compromise and/or permanent disfigurement. 
Hemangiomas are vasoproliferative neoplasms and are divided into 
infantile and congenital depending on age at presentation. Vascular 
malformations are commonly present at birth, usually in the head 
and neck region. They are subdivided into slow flow – a combination 
of capillary, venous and lymphatic – and fast flow, which has an 
arterial component (1). The majority of vascular malformations 
are small or self-limiting as the child grows older, but in some, 
lesions may grow with age. These may be treated surgically or with 
sclerosing agents. Bleomycin (BLM), also known as blenoxane or 
pingamycin, is primarily a cytotoxic anti-tumor antibiotic drug. 
It has sclerosing properties on direct contact with endothelium. 
Compared to surgery, intralesional bleomycin injection (IBI) is a 
simple, practical and noninvasive method of treatment that limits 
the number of secondary procedures (2, 3). BLM was first isolated 
as a Cu2+-containing glyco-oligopeptide antibiotic from the culture 
medium of streptomyces verticullust. It was soon found to be an 
anticancer agent and has since become one of the most widely used 
anticancer drugs (4, 5). We selected bleomycin as first line treatment 
for hemangiomas and vascular malformations, as it was low-cost 
and easily available.
Bleomycin is usually used as an antineoplastic drug to treat 
many kinds of cancer, such as lymphoma, cervical cancer, head and 
neck cancer, and testicular cancer. Bleomycin is the most commonly 
used sclerosing agent for the treatment of vascular anomalies in 
China. Histological investigation shows that bleomycin can cause 
injury and detachment of endothelial cells and lead to narrowing or 
occlusion of the vessels (6).
A variety of techniques are used in the treatment of cutaneous 
hemangiomas and vascular malformations. Laser therapy is most 
effective for superficial lesions, surgical excision and skin flap 
elevation in early childhood, and has the best cosmetic results (7), 
but the technique is technically demanding.
In this study, we present our experience of clinical outcomes 
in treating patients presenting with hemangiomas and vascular 
malformations with bleomycin through ultrasound-guided 
intralesional injection at our tertiary care hospital.
Surgical removal at an early stage of the child’s life would be 
beneficial to reestablish a normal appearance, thus minimizing 
psychosocial problems. However, there is argument among clinicians 
that complete surgical resection is difficult and often involves 
massive bleeding, severe scars, and injury of the facial nerves. The 
main advantages of IBI are the absence of external scarring and the 
low number of complications as compared with surgical treatment. 
Studies show that sclerotherapy is good for small diameter vessels. 
Therefore, intralesional injection of bleomycin in the cervical-facial 
region has been a routine therapy and has proven to be effective for 
the last 20 years (2, 3, 8, 9).
Use of ultrasonography and Doppler is an additional and recent 
technology to the existing treatment procedure to rate the blood 
stream. It allows for unequivocal classification as to venous, arterial, 
or lymphatic malformation, and a simple noninvasive method to 
distinguish slow-flow from fast-flow vascular malformation (10). 
Therefore, if ultrasound guidance technique is used for the patient 
selection, and later in the treatment of hemangiomas and vascular 
malformations, improved results may be seen.
Materials and methods
After IRB approval, a retrospective chart review was conducted 
on patients with a diagnosis of hemangiomas and venous 
malformation located in either the head and neck region (n=28) or 
peripheral (n=2), who were treated between August 2009 and June 
2013. Patient selection was made on the basis of history, clinical 
examination, grey-scale ultrasound, color Doppler and spectral 
Doppler parameters. Lesions with slow and medium flow rates, 
along with very small or non-detectable venous outflow rates, were 
selected for IBI. According to Puig’s classification system of vascular 
malformations, based on anatomical and hemodynamic features, 
these vascular malformations belonged to type 1 and type II lesions 
(Table 1) (11, 12).
Table 1. Puig’s classification scheme.
I.  Isolated malformation without peripheral drainage
II.  Malformation that drains into normal veins
III.  Malformation that drains into dilated veins
IV.  Malformation that represents dysplastic venous ectasia
Both infantile and congenital hemangiomas were included. 
RICH in congenital hemangiomas were excluded, as were multiple 
and midline hemangiomas in infantile hemangiomas. Any patients 
with lesions involving mediastinum or trachea, deep soft tissues or 
arteriovenous malformations and patients with incomplete data 
were excluded.
Patients’ demographic data, including age, sex, weight, location 
and size of the lesion, clinical history, ultrasound images with color, 
spectral and Doppler analysis, bleomycin dose, clinical response, 
side effects, and follow-up were recorded. Color photographs of 
the lesions were taken before, during, and after completion of the 
treatment to help parents see the regression of the lesion over time.
Prior to treatment, all patients underwent a thorough clinical 
evaluation to exclude any systemic disease, and ultrasound 
examination with Doppler and duplex analysis of the lesion were 
performed. Informed consent was acquired from the parents prior 
to commencement of sclerotherapy. 
Procedure
Injections were prepared by dissolving a 15 mg powdered 
bleomycin ampoule in 15 ml of normal saline, giving a bleomycin 
concentration of 1 mg/ml.
In accordance with the published guidelines, the bleomycin dose 
was calculated at 0.5-1 mg / kg of body weight, with a maximum of 
15 mg per session and 40mg per patient (13).
All procedures were performed under general anesthesia. 
Ultrasound scanning was done using a portable Sonosite ultrasound 
machine with a linear array probe (7.5 -10 MHz). Under aseptic 
conditions bleomycin was injected in vascular channels that 
appeared anechoic on grey scale (consistent with vascular channels 
in hemangioma), venous malformations and cystic spaces in 
lymphatic malformation at multiple sites using a 23-gauge needle. 
Following this treatment, local pressure was applied to the soft tissue 
around the lesion in order to prolong contact time of bleomycin 
with the vessel wall. Localized pressure over injection site assured 
hemostasis. Larger lesions required multiple injections.
This procedure required short-stay hospital admission for 
four hours post-procedure observation for local or systemic 
complications. At 3-4 week follow-up, clinical and ultrasound 
assessments were done to evaluate response to treatment, and assess 
whether further bleomycin injection was necessary or not. Lesion 
size was measured, and vascularity by Doppler was documented. 
Clinically, the lesion was evaluated for swelling, discoloration, pain, 
pressure symptoms or ulceration. In absence of optimal response, 
injections were repeated until four treatment sessions had been 
performed, or the lesion was cured.
Treatment response was categorized as: (i) complete resolution 
(>90%); (ii) substantially reduced (<50% reduction); (iii) mildly 
reduced (<25% reduction); or, (iv) no improvement (<10% reduction). 
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Results
A total of thirty patients with hemangiomas and vascular 
malformations were treated with intralesional bleomycin injection 
(Table 2). Twenty-three patients had hemangiomas, and seven 
had vascular malformations (5 lymphatic, 2 venous). Twenty-four 
patients completed the treatment. Treatment of six patients is 
ongoing at the time of writing this report. There were 14 males and 
16 females in the study, ages 8 months to 48 years.
Twenty-eight lesions were located in the head and neck region, 
and two were peripheral. One of the hemangiomas was on the hand, 
involving the little finger, hypothenar eminence and part of the 
distal forearm. The other was on the leg, involving the lateral surface 
of thigh. The rest of the hemangiomas were noticed on the face in 
variable locations: two on the ear lobule, three near the mandible, 
one on the inferior surface of tongue, one on the lower lip, and the 
rest were on either of the cheeks. All lymphatic malformations were 
noted around the neck, whereas two venous malformations were 
located at the mandible.
Eighteen lesions were small to medium in size, measuring 0.5 
-5 cm. Ten lesions were large, at 5-10 cm, and two were extensive, 
measuring larger than 20 cm each in size.
Nine patients had prior treatment, including alcohol/ steroid 
injection and surgery, while the remaining twenty-one patients had 
only the intralesional bleomycin treatment regimen reported here.
Seventeen of the 23 hemangiomas (74%) were completely resolved 
clinically and on ultrasound, while five (22%) showed marked 
improvement and one (4%) showed mild improvement. Of the 
seven vascular malformations, five (71%) lymphatic malformations 
resolved completely, and 2 (29%) venous malformations showed 
substantial improvement. Treatment was maximum in small 
to medium sized lesions, with 17 of 18 (99%) showing marked 
improvement. Among large and extensive legions, 8 of 12 (70%) 
showed marked improvement. Twenty-two patients (73%) received 
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Table 2. Clinical and ultrasound outcomes of bleomycin sclerotherapy in hemangiomas and vascular malformations.
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Case Age Sex Site
Size
(cm) Lesion type
Sclerotherapy 
sessions Clinical outcome
Ultrasound 
outcome
1 1 yr M Neck 6.0 LM 4 >90% >90%
2 13 yrs M Cheek 9 CH 2 -contd >50% >50%
3 15 yrs F Cheek 4 CH 2-contd >90% >90%
4 2 yrs M Mandible 2.5 VM 4 >50% >50%
5 13 yrs M Cheek 6.5 IH 3 >90% >90%
6 16 yrs F Leg 25 CH 4 >25% >25%
7 14 yrs M Cheek 2 IH 4 >90% >90%
8 8 yrs F Cheek 7.8 IH 2-contd >50% >50%
9 20 yrs M Lip 3.8 IH 2 >90% >90%
10 22 yrs M Mandible 4.6 CH 4 >90% >90%
11 3 yrs F Neck 5.5 LM 3 >90% >90%
12 10 mos F Cheek 2.1 IH 2 >90% >90%
13 11 yrs M Mandible 8.5 IH 2 >50% >50%
14 9 yrs F Cheek 2.5 IH 2 >90% >90%
15 5 yrs M Hand 20 CH 2 -contd >50% >50%
16 2 yrs F Neck 3.5 LM 6 >90% >90%
17 10 mos F Ear 5.0 IH 2 >90% >90%
18 9yrs F Cheek 4.4 IH 2 >90% >90%
19 3yrs M Neck 10 LM 2 >90% >90%
20 6 yrs M Mandible 1.5 VM 1 >50% >50%
21 1 yr M Cheek 1.5 IH 1-contd >90% >90%
22 10 yrs F Cheek 3.0 IH 4 >90% >90%
23 11 mos F Cheek 5.8 IH 3 >90% >90%
24 10 mos F Cheek 7.0 IH 3 >90% >90%
25 48 yrs F Tongue 1.5 CH 3 >90% >90%
26 32 yrs M face 4.5 CH 3 >90% >90%
27 20 yrs M Ear 6.2 IH 3 >90% >90%
28 28 yrs F Cheek 1.1 CH 2 >90% >90%
29 1 mos F Neck 10 LM 4 >90% >90%
30 8 mos F Cheek 2.0 IH 3-contd >90% >90%
Abbreviations: IH: infantile hemangioma; CH: congenital hemangioma; LM; lymphatic malformation; VM: venous malformations; contd: continued
only one to three treatment sessions. The maximum number of 
treatments was four sessions, with the exception of one case in 
which a patient’s lymphatic malformation was completely resolved 
after four sessions, but showed recurrence after a year of treatment 
and was markedly reduced after two more sessions (Table 2).
Overall treatment was completed in twenty-four patients (96%) of 
patients. Two patients underwent major surgery due to insignificant 
response to bleomycin. These patients had hemangiomas in 
extremities, with lesions greater than 20 cm. Twenty-two patients 
did not require additional treatment. Twenty-three of 24 patients 
(95.3%) showed overall improvement, with no residual lesion and 
scarring according to the parents’ and clinicians’ observation, as 
well as ultrasound follow-up. All patients who received complete 
treatment presented with swelling. Twelve of thirteen patients 
(92%) who presented with discoloration of the skin overlying the 
lesion showed complete to marked resolution (Table 3). There were 
few bleomycin-related complications: one patient had fever, which 
subsided within 24 hours with antipyretics; one patient developed 
minor superficial ulceration, likely due to bleomycin leakage into 
the superficial tissues, which healed over four weeks time, leaving 
minimum scarring. There were no cases of pulmonary fibrosis 
(Table 4).
Immediate Complications No. of patients
Fever 1
Vomiting 1
Flu 0
Late Complications No. of patients
Ulceration 1
Coughing 0
Pulmonary fibrosis 0
Case descriptions
Case 1:  8 year-old female presented with left cheek hemangioma 
measuring 7.8 cm x 3.5 cm on ultrasound, with no prior treatment 
received. Intralesional bleomycin was administered in doses of 10 
mg per session (Fig 1).
Same patient after two treatment sessions of intralesional 
bleomycin, at an interval of one session per month. The patient was 
followed up for two years at six monthly intervals, and shows no 
recurrence (Fig 2).
Case 2: Female age 2 years presented with swelling on neck present 
since birth. Figure 3 shows part of large macrocystic lymphatic malfor-
mation measuring 3.5 cm x 1.1 cm on ultrasound. Excellent response 
was observed clinically and >50% reduction on ultrasound after first 
session of U/S guided IBI (Fig. 4).
Case 3: Swelling in left mandible in female age 3 years 11 months 
present since 18 months of age. On ultrasound mixed lymphatic mal-
formation can be seen in Figure 5. Complete resolution with no cystic 
spaces and only residual fibrotic tissue after three treatment sessions 
(Fig. 6).
Case 4: 22 year-old male with hemangioma in right cheek measuring 
5.7 cm x 2.7 cm presenting as hypervascular on color Doppler (Fig. 
7a/7b). Follow up after first injection shows reduction of up to 2.9 cm 
x 1.6 cm, with blood flow reduced by more than 90% (Fig. 8a/8b).
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Table 3. Overall clinical response of 30 heamangioma/vascular malformation patients treated with Intralesional bleomycin injections at The Indus 
Hospital, Karachi (2009-2013).
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Treatment  outcome
 Treatment completed
(n=24)
Treatment continued
(n=6) Overall
Completely resolved or substan-
tially reduced 23 (95.8%) 3 (50%) 26 (86.7%)
Mildly reduced 1 (4.2%) 3 (50%) 4 (13.3%)
Table 4. Complications encountered in patients treated with intrale-
sional bleomycin injection.
Fig. 1. 8 year-old female 
presenting with left cheek 
hemangioma.
Fig. 2. Same patient as in Fig. 1 
after two treatment sessions of 
intralesional bleomycin, at an in-
terval of one session per month.
Fig. 3. Part of large macrocystic lymphatic malformation on neck pres-
ent since birth in 2 year-old female.
July 20165/8  | 10.7191/jgr.2016.1022 Journal of Global Radiology
Memon, Malik, Anjum, Ahmed and Saeed (2016)JGR
Fig. 4. Greater than 50% reduction on ultrasound after first session of 
U/S guided IBI.
Fig. 5. Swelling in left mandible in female age 3 years 11 months, 
present since 18 months of age. On ultrasound mixed lymphatic mal-
formation.
Fig. 6. Complete resolution with no cystic spaces and only residual 
fibrotic tissue after three treatment sessions.
Fig. 7a. Hemangioma in right cheek of 22 year-old male, measuring 5.7 
cm x 2.7 cm and presenting as hypervascular on color Doppler.
Fig. 7b. Hemangioma in right cheek of 22 year-old male, measuring 
5.7 cm x 2.7 cm and presenting as hypervascular on color Doppler. 
Fig. 8a. Same patient as in Fig. 7a/7b after first injection; substantial 
reduction apparent with blood flow reduced more than 90%.
Discussion
A new classification adopted by the International Society for 
the Study of Vascular Anomalies (ISSVA) in 1996, based on that 
described by Mulliken and Glowacki (1), shows that vascular 
lesions now include vasoproliferative neoplasms and vascular 
malformations. Hemangiomas, the most common vasoproliferative 
neoplasms, are classified as infantile and congenital hemangiomas. 
Infantile hemangiomas present between the second and ninth 
weeks of life. They undergo a proliferative growth phase until they 
reach their full size. Congenital hemangiomas, on the other hand, 
are fully formed at birth (14). Both types are characterized by 
endothelial proliferation (15). They are more common in females, 
80% occurring in the head and neck.  Based on the natural history of 
hemangiomas, 50% completely resolved by age 5 and 70% by 7 years 
of age. Improvement may or may not occur in the remaining (16).
Two main types of congenital hemangiomas have been described: 
Non-involuting congenital hemangiomas (NICH), which present at 
birth and show proportional growth without regression, and rapidly 
involuting congenital hemangiomas (RICH), which present at birth 
and regress completely within two years (14). 
Although cutaneous hemangiomas are most common and easily 
identified, they can also occur in extracutaneous sites, including the 
liver, gastrointestinal tract, central nervous system, pancreas, gall 
bladder, thymus, spleen, lymph nodes, lung, urinary bladder and 
adrenal glands (17).
Vascular malformations are always present at birth, and, unlike 
hemangiomas, have normal endothelial turnover. They grow 
progressively in size with age, and never involute spontaneously. 
Increase in size may occur due to infection, trauma, bleeding or 
hormonal changes. Vascular malformations are subdivided into 
capillaries, veins, arteries, lymphatics, or a combination of these 
vessel types. Haemodynamically, the vascular malformations can be 
further divided into high-flow or low-flow lesions (1, 18). Capillary, 
lymphatic and venous malformations are classified as slow-flow 
lesions, and arterial malformations, arteriovenous fistulas, and 
arteriovenous malformations are classified as high-flow lesions 
(8, 19, 20). Lymphatic malformations (LMs) are developmental 
anomalies consisting of abnormally formed lymphatic channels 
and cystic spaces of varying size. Morphologically, LMs include: 
microcystic, macrocystic, and mixed. The macrocystic type is 
comprised of single or multiloculated cysts that vary in size from 
a few millimeters to several centimeters. Microcystic LMs contain 
variable fibrous/fatty components, tiny cysts, or ectatic channels 
(21). Treatment is indicated when the lesions become symptomatic 
by causing functional disturbances, or for disfigurement or cosmetic 
reasons (1, 18).
Several treatment options are available for above-vascular lesions: 
plastic surgery, embolization and sclerotherapy. Sclerotic therapy 
may be achieved by intralesional injections of corticosteroids, use 
of interferon, or by laser therapy, cryosurgery or radiations (22). 
Surgical excision and sclerotherapy are most commonly used in 
clinical practice. Plastic surgery intervention is reserved for deep 
lesions. But it is often associated with massive bleeding, and poor 
cosmetic results from scarring or nerve injury.  Laser therapy is 
effective only for small and superficial lesions (7).
Propanolol has recently been used to treat infantile hemangiomas. 
Other drugs include steroids followed by chemotherapeutic agents, 
such as vincristine (23, 24).
Selection of the treatment modality depends on the type, 
location, and size of the lesions, as well as the treatment cost and 
techniques available. Each of these approaches has advantages and 
disadvantages based on clinical results. Percutaneous sclerotherapyis 
regarded as a minimally invasive, low-cost and reliable modality for 
the treatment. It involves injection of a sclerosant into the lesion 
through the skin. It is usually safe and effective for small to medium 
sized lesions. Previous studies have shown that sclerotherapy 
is a helpful preoperative adjunct treatment for larger lesions. It 
can reduce surgical blood loss and decrease the area of surgical 
resection (25). The main advantages are no external scarring and 
few complications, as compared with surgical treatment. Therefore, 
sclerotherapy is selected as a better alternative in the treatment of 
vascular malformations and hemangiomas in the face and neck (7, 
8, 21, 26). 
Many sclerosants, including boiling water, sodium morrhuate, 
absolute ethanol, sodium tetradecyl sulfate, and bleomycin (7, 
8) have been attempted in treating hemangiomas and vascular 
malformations. Bleomycin is an antineoplastic agent that has been 
reported to successfully treat lymphatic malformations (27, 28) and, 
in smaller studies, hemangiomas (29, 30). Bleomycin has been used 
as alternative sclerosant as it has been shown to have a sclerosant 
effect on endothelial cells of the cyst wall of lymphangiomas (29-32).
The mechanism of action of bleomycin involves swelling 
of endotheial cells and discontinuation of tunica intima with 
increased thickness of the walls leading to narrowing of the lumen 
and ultimately occlusion (6, 13). Proper injections into the vascular 
spaces leads to gradual fibrous degeneration and resultant lesion 
regression, with no fibrosis and scarring. It is a minimally invasive 
treatment with good results, and has therefore been in use for last 
two decades (2, 3, 9, 13, 28, 33).
We compared our report with other larger series of bleomycin 
treatment of maxillofacial hemangiomas. Our technique was 
similar to that reported earlier. A 1.0 mg/ml concentration was 
used, though Zheng et al. used a concentration of 2 mg/ml for 
the venous malformations. We conducted up to four sessions per 
patient; others reported 1-5 sessions, with an average of 3.5 sessions. 
Bleomycin injection is generally safe, with reversible complications 
such as fever and vomiting. One patient (3%) suffered from skin 
ulceration, but in a larger series of 249 and 66 patients, no ulceration 
was reported (13,16).  We report a high degree of success, with 
96% of hemangiomas cured or substantially reduced. Zheng et al. 
report a lower success rate of 75-84% for venous and lymphatic 
malformations. In another series, Hou et al. achieved 88% cure or 
substantial reduction in 66 patients. It is possible our results are 
better than larger series due to our smaller patient cohort (13,16).  
There were no cases of pulmonary fibrosis among patients in this 
study. Pulmonary fibrosis is a known complication and has been 
reported in some oncology patients who received a high cumulative 
dose of bleomycin. Some studies have indicated a risk of pulmonary 
fibrosis in patients receiving more than 160 mg of bleomycin 
systemically (31). It is reported that the total dose must not exceed 5 
mg/kg, or approximately 20 mg in total, for this to occur in infants 
(22).
Bleomycin injection without ultrasound guidance is based on 
clinical examination, and injection into the lesion after aspiration of 
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Fig. 8b. Same patient as in Fig. 7a/7b after first injection; substantial 
reduction apparent with blood flow reduced more than 90%.
July 20167/8  | 10.7191/jgr.2016.1022 Journal of Global Radiology
blood. It has been faced with problems including dispersion of drug 
into surrounding tissue with significantly reduced therapeutic effect, 
or invasion of important tissues adjacent to the lesion such as nerves, 
salivary glands or vessels, which can lead to serious complications. 
Ultrasound guidance was first used by Yamaki (32)with VMs in the 
cervical-facial region by intralesional injection of absolute alcohol, 
and he researched this method in detail with reported advantages 
like prevention of intra-arterial injections (34, 35).
In this study, we evaluated the therapeutic outcome of injection 
of bleomycin in treatment of hemangiomas and VMs. The ultrasound 
imaging evaluated the size of lesions, macro/microcystic, tissue plane 
occupied, and the relationship between lesions and surrounding 
tissues, so that the effects of treatment could be improved by 
ensuring the precise injection position. The Doppler scan showed 
the vascularity and velocity of flow. It was observed that that there 
are certain factors that affected outcomes: type of lesion, the size and 
location of the malformations.
Conclusion
These encouraging results were mainly relevant to the precise 
injection of bleomycin into lesions under ultrasound guidance, 
which made the drug concentrations localize in the lesion so as to 
improve the therapeutic effect and reduce complications. However, 
there are some weaknesses in this study. First, there was no control 
group in this report. We only did a retrospective study, not a 
prospective one. Second, only superficial lesions were included, as 
MRI was not available in our setup and patients could not afford 
MRI from another institute.
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